Petros P. Sfikakis
Petros P. Sfikakis
Professor of Internal Medicine & Rheumatology, Medical School, National and Kapodistrian University of Athens, Greece
Verified email at
Cited by
Cited by
EULAR recommendations for the management of Behçet disease
G Hatemi, A Silman, D Bang, B Bodaghi, AM Chamberlain, A Gul, ...
Annals of the rheumatic diseases 67 (12), 1656-1662, 2008
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
C Gabay, P Emery, R van Vollenhoven, A Dikranian, R Alten, K Pavelka, ...
The Lancet 381 (9877), 1541-1550, 2013
Effect of infliximab on sight-threatening panuveitis in Behcet's disease
PP Sfikakis, PG Theodossiadis, CG Katsiari, P Kaklamanis, ...
The Lancet 358 (9278), 295-296, 2001
Nintedanib for systemic sclerosis–associated interstitial lung disease
O Distler, KB Highland, M Gahlemann, A Azuma, A Fischer, MD Mayes, ...
New England Journal of Medicine 380 (26), 2518-2528, 2019
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down‐regulation of the T cell costimulatory molecule CD40 ligand: an open‐label trial
PP Sfikakis, JN Boletis, S Lionaki, V Vigklis, KG Fragiadaki, A Iniotaki, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2005
Anti-TNF therapy in the management of Behçet's disease—review and basis for recommendations
PP Sfikakis, N Markomichelakis, E Alpsoy, S Assaad-Khalil, B Bodaghi, ...
Rheumatology 46 (5), 736-741, 2007
2018 update of the EULAR recommendations for the management of Behçet’s syndrome
G Hatemi, R Christensen, D Bang, B Bodaghi, AF Celik, F Fortune, ...
Annals of the rheumatic diseases 77 (6), 808-818, 2018
Waldenstrom’s macroglobulinemia: clinical features, complications, and management
MA Dimopoulos, P Panayiotidis, LA Moulopoulos, P Sfikakis, M Dalakas
Journal of Clinical Oncology 18 (1), 214-214, 2000
Psoriasis induced by anti–tumor necrosis factor therapy: a paradoxical adverse reaction
PP Sfikakis, A Iliopoulos, A Elezoglou, C Kittas, A Stratigos
Arthritis & Rheumatism: Official Journal of the American College of …, 2005
Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients
A Arida, K Fragiadaki, E Giavri, PP Sfikakis
Seminars in arthritis and rheumatism 41 (1), 61-70, 2011
The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions
PP Sfikakis
TNF pathophysiology 11, 180-210, 2010
Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades–Behcet disease
PP Sfikakis, PH Kaklamanis, A Elezoglou, N Katsilambros, ...
Annals of Internal Medicine 140 (5), 404-406, 2004
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal
I Mavrikakis, PP Sfikakis, E Mavrikakis, K Rougas, A Nikolaou, ...
Ophthalmology 110 (7), 1321-1326, 2003
Behcet’s disease: a new target for anti-tumour necrosis factor treatment
PP Sfikakis
Annals of the rheumatic diseases 61 (suppl 2), ii51-ii53, 2002
Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations
S Kalra, A Silman, G Akman-Demir, S Bohlega, A Borhani-Haghighi, ...
Journal of neurology 261 (9), 1662-1676, 2014
Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors
A Herbert, JK Cruickshank, S Laurent, P Boutouyrie
European heart journal 35 (44), 3122-3133, 2014
The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis
A Arida, M Kyprianou, M Kanakis, PP Sfikakis
BMC Musculoskeletal Disorders 11 (1), 1-8, 2010
Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study
KS Stamatelopoulos, GD Kitas, CM Papamichael, E Chryssohoou, ...
Arteriosclerosis, thrombosis, and vascular biology 29 (10), 1702-1708, 2009
Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future
PP Sfikakis, JN Boletis, GC Tsokos
Current opinion in rheumatology 17 (5), 550-557, 2005
Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis
PP Sfikakis, VL Souliotis, KG Fragiadaki, HM Moutsopoulos, JN Boletis, ...
Clinical immunology 123 (1), 66-73, 2007
The system can't perform the operation now. Try again later.
Articles 1–20